A new form of 'nanosized' aspirin to overcome 'aspirin resistance'

Sep 04, 2013
A new form of aspirin to overcome ‘aspirin resistance’
Scientists are developing a new form of aspirin to overcome “aspirin resistance,” which affects millions of people who could otherwise benefit from the drug commonly used to prevent heart attack and stroke. Credit: Photos.com/Thinkstock

Scientists are reporting development of a new form of aspirin—taken daily by about 60 million people in the United States alone to reduce the risk of heart attack and stroke—that could extend aspirin's benefits to people who may not respond to the drug. Their advance toward coping with "aspirin resistance" appears in the journal ACS Nano.

Shiqi Peng, Ming Zhao and colleagues note that aspirin lowers by keeping called platelets from clumping and forming clots. But some experts believe that aspirin doesn't work for millions of people, who may switch to more costly, potent with more serious side effects. Scientists have tried to address aspirin resistance by combining it with other drugs. But Peng and Zhao say that the problem remains. Their research group decided to modify aspirin in an effort to make it work for more people.

They linked aspirin to a carrier consisting of a fragment of protein that can transport aspirin directly to damaged parts of blood vessels where clots form. Experiments with , stand-ins for humans in such early tests, showed that the carrier delivered aspirin to areas of blood vessels where clots were forming. It released aspirin inside the developing clot and stopped the clot-formation process.

A new form of aspirin to overcome 'aspirin resistance'

The article is titled "Nano-Sized Aspirin-Arg-Gly-Asp-Val: Delivery of Aspirin to Thrombus by the Target Carrier Arg-Gly-Asp-Val Tetrapeptide."

Explore further: Research reveals how our bodies keep unwelcome visitors out of cell nuclei

More information: Nanosized Aspirin-Arg-Gly-Asp-Val: Delivery of Aspirin to Thrombus by the Target Carrier Arg-Gly-Asp-Val Tetrapeptide, ACS Nano, Article ASAP. DOI: 10.1021/nn402171v

Abstract
Resistance and nonresponse to aspirin dramatically decreases its therapeutic efficacy. To overcome this issue, a small-molecule thrombus-targeting drug delivery system, aspirin-Arg-Gly-Asp-Val (A-RGDV), is developed by covalently linking Arg-Gly-Asp-Val tetrapeptide with aspirin. The 2D ROESY NMR and ESI-MS spectra support a molecular model of an A-RGDV tetramer. Transmission electron microscopy images suggest that the tetramer spontaneously assembles to nanoparticles (ranging from 5 to 50 nm in diameter) in water. Scanning electron microscopy images and atomic force microscopy images indicate that the smaller nanoparticles of A-RGDV further assemble to bigger particles that are stable in rat blood. The delivery investigation implies that in rat blood A-RGDV is able to keep its molecular integrity, while in a thrombus it releases aspirin. The in vitro antiplatelet aggregation assay suggests that A-RGDV selectively inhibits arachidonic acid induced platelet aggregation. The mechanisms of action probably include releasing aspirin, modifying cyclic oxidase, and decreasing the expression of GPIIb/IIIa. The in vivo assay demonstrates that the effective antithrombotic dose of A-RGDV is 16700-fold lower than the nonresponsive dose of aspirin.

add to favorites email to friend print save as pdf

Related Stories

Dipyrone negates aspirin's antiplatelet effect

Aug 22, 2013

(HealthDay)—There is an unfavorable pharmacological drug interaction between the non-narcotic analgesic dipyrone and aspirin in patients with coronary artery disease (CAD), according to research published online Aug. 14 ...

OK to continue aspirin therapy up to pancreatic surgery

Aug 01, 2013

(HealthDay)—Patients on aspirin therapy do not have higher rates of perioperative bleeding, transfusion, or major procedure-related complications following elective pancreatic surgery, according to research ...

Aspirin resistant proteins are identified

Jun 26, 2007

Spanish scientists have identified blood proteins that might create aspirin resistance that keeps thousands of people from reaping aspirin's benefits.

Aspirin not always best treatment for many individuals

May 16, 2013

(Medical Xpress)—An aspirin a day may not always keep heart disease away, say two University of Florida cardiologists. But a new algorithm they have developed outlines factors physicians should weigh as ...

Recommended for you

A gut reaction

Nov 19, 2014

Queen's University biologist Virginia Walker and Queen's SARC Awarded Postdoctoral Fellow Pranab Das have shown nanosilver, which is often added to water purification units, can upset your gut. The discovery ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.